Moleculin Biotech announces granting of two new U.S. patents – TipRanks
Moleculin Biotech announces granting of two new U.S. patents TipRanks
PATENT NEWS
-
In: PATENT NEWS
-
In: PATENT NEWS
FDA Fast Track Cancer Drug Annamycin Gets Crucial Patent Protection Through 2040 – Stock Titan
FDA Fast Track Cancer Drug Annamycin Gets Crucial Patent Protection Through 2040 Stock Titan
-
In: PATENT NEWS
Flux Power Awarded Patent for an Intelligent Battery Cycle Life Maximization Algorithm, Pioneering the Future of AI-Driven Energy Optimization – Business Wire
Flux Power Awarded Patent for an Intelligent Battery Cycle Life Maximization Algorithm, Pioneering the Future of AI-Driven Energy Optimization Business Wire
-
In: PATENT NEWS
Alpha Modus settles patent lawsuit with Kroger – Investing.com
Alpha Modus settles patent lawsuit with Kroger Investing.com
-
In: PATENT NEWS
NRx Pharmaceuticals seeks patent for preservative-free ketamine – Investing.com
NRx Pharmaceuticals seeks patent for preservative-free ketamine Investing.com
-
In: PATENT NEWS
Alpha Modus Reaches Settlement Agreement With Kroger In Patent Litigation – marketscreener.com
Alpha Modus Reaches Settlement Agreement With Kroger In Patent Litigation marketscreener.com
-
In: PATENT NEWS
Alpha Modus Reaches Settlement Agreement with Kroger in Patent Litigation – The Manila Times
Alpha Modus Reaches Settlement Agreement with Kroger in Patent Litigation The Manila Times
-
In: PATENT NEWS
Amazon Patent Evaluation Express (APEX): Personal Jurisdiction Considerations – Mondaq
Amazon Patent Evaluation Express (APEX): Personal Jurisdiction Considerations Mondaq
-
In: PATENT NEWS
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine – Kilgore News Herald
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine Kilgore News Herald
-
In: PATENT NEWS
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine – PR Newswire
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine PR Newswire